(function(){ var content_array=["

衛材簡介<\/strong><\/p> \n

衛材在中國腦健康領域耕耘二十多年，一直秉承關心人類健康（human health care）的企業使命，始終支持"腦健康行動"所提出的各項主張和措施，并積極參與AD科普手冊科普宣傳。關注記憶健康，提倡早篩、早診、早治，不僅是公司的責任，也是作為社會成員的責任。<\/p> \n

[1] 中國癡呆與認知障礙指南寫作組,中國醫師協會神經內科醫師分會認知障礙疾病專業委員會.2018中國癡呆與認知障礙診治指南(一):癡呆及其分類診斷標準.中華醫學雜志.2018;98(13):965-970
<\/sup>[2] Jia L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China<\/span>: a cross?sectional study. Lancet Public Health. 2020;5(12): e661?e671
<\/sup>[3] Jia J, et al.Alzheimers Dement. 2018 Apr;14(4):483 491.
<\/sup>[4] Cummings J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin Transl Sci. 2018;11(2):147-152
<\/sup>[5] Michael C. Irizarry<\/span>, AAIC 2023 presentation"Lecanemab : Amyloid Reduction and Evidence of Downstream Biomarker Modification".
<\/sup>[6] lecanemab-irmb injection (LEQEMBI®<\/sup>), FDA label（ 202307）
<\/sup>[7] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease[J]. N Engl J Med,  2023, 388(1):9-21
<\/sup>[8] Keith Johnson<\/span>. CTAD 2023 presentation"Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker".<\/sup><\/p> \n

 <\/p> \n

\n  \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();
<center id="kgssg"></center>
<center id="kgssg"><wbr id="kgssg"></wbr></center>
<noscript id="kgssg"><option id="kgssg"></option></noscript><optgroup id="kgssg"><wbr id="kgssg"></wbr></optgroup><optgroup id="kgssg"></optgroup>
<optgroup id="kgssg"><div id="kgssg"></div></optgroup>
<center id="kgssg"><div id="kgssg"></div></center>
<center id="kgssg"></center>
久久久亚洲欧洲日产国码二区